Bioventus Inc. $BVS Position Increased by Royce & Associates LP

Royce & Associates LP grew its position in Bioventus Inc. (NYSE:BVS) by 15.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,262,976 shares of the company’s stock after buying an additional 170,900 shares during the quarter. Royce & Associates LP’s holdings in Bioventus were worth $8,449,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in BVS. PharVision Advisers LLC purchased a new stake in shares of Bioventus in the 2nd quarter valued at approximately $67,000. Covestor Ltd lifted its holdings in shares of Bioventus by 28.0% in the third quarter. Covestor Ltd now owns 9,951 shares of the company’s stock valued at $67,000 after purchasing an additional 2,176 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Bioventus in the second quarter worth $72,000. HB Wealth Management LLC purchased a new position in shares of Bioventus during the third quarter valued at $72,000. Finally, Olympiad Research LP acquired a new position in Bioventus during the third quarter valued at $74,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

Bioventus Price Performance

Shares of NYSE:BVS opened at $8.74 on Wednesday. The business has a fifty day simple moving average of $8.05 and a 200 day simple moving average of $7.47. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a 1 year low of $5.81 and a 1 year high of $11.25. The firm has a market cap of $723.35 million, a price-to-earnings ratio of -14.33 and a beta of 0.80.

Analyst Ratings Changes

Separately, Barrington Research initiated coverage on Bioventus in a research note on Monday, February 9th. They set an “outperform” rating and a $13.00 target price on the stock. Four analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $13.75.

Insider Activity

In other news, Director Guy P. Nohra sold 10,000 shares of Bioventus stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $7.57, for a total transaction of $75,700.00. Following the completion of the sale, the director directly owned 116,610 shares in the company, valued at $882,737.70. The trade was a 7.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 33.00% of the stock is currently owned by corporate insiders.

About Bioventus

Bioventus, Inc (NYSE: BVS) is a global medical technology company focused on providing innovative therapeutic solutions to enhance patient care in musculoskeletal health. The company develops, manufactures, and markets a range of products designed to promote bone healing, support joint health, and relieve pain non-invasively. Bioventus leverages biologic and biophysical approaches to deliver effective therapies that aim to accelerate recovery times and improve overall patient outcomes.

Bioventus’s product portfolio includes its flagship EXOGEN® Bone Healing System, an ultrasound-based device indicated for non-union fractures and fracture healing enhancement.